Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Company Deals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Fineline Cube May 19, 2026
Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri

Fineline Cube May 19, 2026
Company Drug

Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease

Fineline Cube May 19, 2026
Company Drug

BeiGene’s Tislelizumab Secures 12th Indication Approval in China for HCC First-Line Treatment

Fineline Cube Jan 3, 2024

BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received approval...

Company Drug

BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments

Fineline Cube Jan 3, 2024

The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...

Company Deals

Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization

Fineline Cube Jan 3, 2024

Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...

Company Deals

Orient Gene Biotech to Acquire Hangzhou Laihe Biotech, Expanding POCT and AI in Healthcare

Fineline Cube Jan 3, 2024

Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to...

Company Deals

Shanghai Teogen Life Technology and China National Medical Device Form Strategic Partnership

Fineline Cube Jan 3, 2024

Shanghai Teogen Life Technology Co., Ltd, a Chinese-based company, has announced a strategic partnership with...

Company Deals

Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management

Fineline Cube Jan 3, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China,...

Company Legal / IP

Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France

Fineline Cube Jan 2, 2024

French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...

Company Legal / IP

J&J Shareholders Cleared to Sue Over Hidden Asbestos Risks in Talc Products

Fineline Cube Jan 2, 2024

A US federal court has granted permission for certain Johnson & Johnson (J&J; NYSE: JNJ)...

Policy / Regulatory

China’s CDE Releases Guidelines for CGT Clinical Trials Communication

Fineline Cube Jan 2, 2024

The Center for Drug Evaluation (CDE) in China has released the “Technical Guiding Principles for...

Policy / Regulatory

China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released...

Policy / Regulatory

China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued...

Company Deals

Roche to Expand Diagnostics Portfolio with Acquisition of LumiraDx Technology

Fineline Cube Jan 2, 2024

Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative...

Company Drug

Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment

Fineline Cube Jan 2, 2024

US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd.,...

Company Deals

Roche Secures Diagnostics Deal with LumiraDx for $295M

Fineline Cube Jan 2, 2024

Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology...

Company Deals

Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug

Fineline Cube Jan 2, 2024

vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...

Company Drug

Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study

Fineline Cube Jan 2, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment

Fineline Cube Jan 2, 2024

Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...

Company Drug

Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Gets US FDA Approval for Clinical Trials

Fineline Cube Jan 2, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Deals

CareRay Digital Medical Technology to Acquire 30% Stake in UK’s ISDI for USD 15.2 Million

Fineline Cube Jan 2, 2024

CareRay Digital Medical Technology Co., Ltd, a company based in Suzhou (SHA: 688607), has announced...

Company Deals

Jiangsu Hengrui’s SHR-A2009 Earns Fast-Track Status for Metastatic NSCLC Treatment

Fineline Cube Jan 2, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that its in-house developed antibody-drug conjugate...

Posts pagination

1 … 424 425 426 … 668

Recent updates

  • Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri
  • GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams
  • Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B
  • Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC
  • Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri

Company

GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams

Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.